Advanced Search

 

Study ID Status Title Patient Level Data
100013 Completed A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage Study Listed on ClinicalStudyDataRequest.com
100151 Completed A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer
100181 Terminated An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Study Listed on ClinicalStudyDataRequest.com
100185 Completed A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Study Listed on ClinicalStudyDataRequest.com
100193 Completed A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease Study Listed on ClinicalStudyDataRequest.com
100262 Completed A Phase I, Open-Label, Multicentre, Dose-escalation Study of Oral GW572016 in Combination with Radiation Therapy and Cisplatin in Patients with Stage III-IV Squamous Cell Carcinoma of the Head and Neck
100273 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes Study Listed on ClinicalStudyDataRequest.com
100310 Completed A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Study Listed on ClinicalStudyDataRequest.com
100344 Completed A 28-Week, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Extended Release AVANDAMET in Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
100349-054 Completed Phase III study to determine immunogenicity and reactogenicity of investigational influenza vaccine formulation I compared to the standard influenza vaccine of GSK Biologicals’ Influsplit SSW®/Fluarix™2003/2004 and compared to an investigational influenza vaccine formulation II in subjects aged over 18 years Study Listed on ClinicalStudyDataRequest.com
100350-055 Completed A phase III double-blind randomized multicentric study to determine the reactogenicity of an investigational influenza vaccine compared to the standard influenza vaccine of GlaxoSmithKline Biologicals’ Influsplit SSW®/ Fluarix™ 2003/2004 in subjects aged over 18 years. Study Listed on ClinicalStudyDataRequest.com
100351 Completed To determine the immunogenicity and reactogenicity of a thiomersal free trivalent influenza split vaccine 2003/2004 or of GSK Biologicals’ standard formulation Influsplit SSW®/Fluarix™ 2003/2004 in children aged from 6 months until 6 years Study Listed on ClinicalStudyDataRequest.com
100381 Completed Study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa) Study Listed on ClinicalStudyDataRequest.com
100382 Completed Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines Study Listed on ClinicalStudyDataRequest.com
100386 (EXT Y5) Completed Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose Study Listed on ClinicalStudyDataRequest.com
100388 Completed Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Study Listed on ClinicalStudyDataRequest.com
100406/004 Completed A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120 Study Listed on ClinicalStudyDataRequest.com
100414 Completed An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects with Recurrent or Persistent Endometrial Cancer
100448 Completed Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers Study Listed on ClinicalStudyDataRequest.com
100449 Completed Long-term Follow-Up studies at Years 16-20, to evaluate the persistence of immune response of GSK Biologicals’ hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group Study Listed on ClinicalStudyDataRequest.com
100450 Completed Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA hepatitis B vaccine with or without hepatitis B immunoglobulins (HBIg) in newborns of HBeAg+ mothers. Study Listed on ClinicalStudyDataRequest.com
100468 Completed An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease Study Listed on ClinicalStudyDataRequest.com
100470 Completed A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
100478 Completed Study to show non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix™-HepB/Hiberix™ without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants Study Listed on ClinicalStudyDataRequest.com
100480 Completed Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix™-HBV, its non-inferiority to Tritanrix™-HBV/Hiberix™ with or without Meningitec™, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.